Theravance Biopharma (TBPH) Competitors

Theravance Biopharma (NASDAQ:TBPH) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends.

Does the media prefer TBPH or AGIO?

In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 5 mentions for Theravance Biopharma. Agios Pharmaceuticals' average media sentiment score of 1.14 beat Theravance Biopharma's score of -0.09 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer TBPH or AGIO?

Agios Pharmaceuticals received 149 more outperform votes than Theravance Biopharma when rated by MarketBeat users. Likewise, 66.98% of users gave Agios Pharmaceuticals an outperform vote while only 62.87% of users gave Theravance Biopharma an outperform vote.

Company	Underperform	Outperform
Theravance Biopharma	Outperform Votes 342 62.87%	Underperform Votes 202 37.13%
Agios Pharmaceuticals	Outperform Votes 491 66.98%	Underperform Votes 242 33.02%

Do analysts prefer TBPH or AGIO?

Theravance Biopharma currently has a consensus target price of $13.75, indicating a potential upside of 46.43%. Agios Pharmaceuticals has a consensus target price of $56.57, indicating a potential upside of 83.61%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Agios Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

Is TBPH or AGIO more profitable?

Agios Pharmaceuticals has a net margin of 1,845.92% compared to Theravance Biopharma's net margin of -78.18%. Agios Pharmaceuticals' return on equity of -2.51% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	-78.18%	-24.79%	-13.43%
Agios Pharmaceuticals	1,845.92%	-2.51%	-2.26%

Which has more volatility & risk, TBPH or AGIO?

Theravance Biopharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Which has better earnings and valuation, TBPH or AGIO?

Agios Pharmaceuticals has lower revenue, but higher earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$64.38M	7.22	-$55.19M	-$1.15	-8.17
Agios Pharmaceuticals	$36.50M	48.37	$673.72M	$11.34	2.72

Do institutionals & insiders have more ownership in TBPH or AGIO?

99.1% of Theravance Biopharma shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Agios Pharmaceuticals beats Theravance Biopharma on 15 of the 18 factors compared between the two stocks.